EIKN (NASDAQ:EIKN) Receives $25.60 Average Price Target from Analysts

Shares of EIKN (NASDAQ:EIKN) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $25.60.

Several equities analysts have recently commented on EIKN shares. Cantor Fitzgerald assumed coverage on EIKN in a research note on Monday, March 2nd. They issued an “overweight” rating on the stock. Wedbush began coverage on EIKN in a research report on Thursday, February 26th. They set an “underperform” rating and a $7.00 price objective for the company. Wall Street Zen upgraded shares of EIKN from a “sell” rating to a “hold” rating in a report on Saturday. Mizuho started coverage on shares of EIKN in a research report on Monday, March 2nd. They issued an “outperform” rating and a $26.00 target price on the stock. Finally, Zacks Research raised shares of EIKN to a “hold” rating in a research note on Friday, February 27th.

EIKN Stock Performance

Shares of EIKN stock opened at $9.81 on Friday. EIKN has a fifty-two week low of $9.81 and a fifty-two week high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.